Prinzi Antonio, Kuiper Jelka, van der Wiel Adorée M, van Velthuysen Marie-Louise F, van Cruchten Remco T P, Brosens Lodewijk A A, de Herder Wouter W, Hofland Johannes
Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Medical Center, Catania, Italy.
Department of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Endocr Oncol. 2025 Jul 11;5(1):e250030. doi: 10.1530/EO-25-0030. eCollection 2025 Jan.
Congenital glucose-galactose malabsorption (CGGM) is a rare autosomal recessive disorder caused by a biallelic mutation of solute carrier family 5 member 1 (), encoding the sodium-dependent glucose transport-1 (SGLT-1) protein. Patients with CGGM present with neonatal-onset osmotic diarrhea due to impaired intestinal uptake of glucose. Here, we report a case of a 41-year-old female with CGGM who was referred to our clinic for symptoms of hypoglycemia, with the final diagnosis of an insulinoma, which was successfully resected. Whole genome sequencing of tumor DNA revealed chromosomal aberrations, without the presence of driver mutations. Given the unknown long-term sequelae of SGLT-1 loss of function in adulthood, this first case of insulinoma in a CGGM patient potentially uncovers a new phenotype resulting from decades of imbalance in glucose homeostasis. We hypothesize that SGLT-1 might play a role in the plasticity of pancreatic β-cells and suggest mechanisms through which CGGM patients could potentially have a higher risk of developing insulinoma in adulthood.
This is the first documented case of insulinoma in a patient with CGGM, suggesting a potential new link between glucose absorption disorders and pancreatic neuroendocrine tumors.The loss-of-function mutation in SGLT-1 due to an SLC5A1 gene mutation may impact pancreatic β-cell plasticity, potentially contributing to insulinoma development through altered glucose homeostasis.The patient's long-term high-fat, low-carbohydrate diet may have played a role in β-cell stimulation via increased levels of GLP-1 and GIP, both of which promote β-cell proliferation and survival.
先天性葡萄糖 - 半乳糖吸收不良(CGGM)是一种罕见的常染色体隐性疾病,由溶质载体家族5成员1()的双等位基因突变引起,该基因编码钠依赖性葡萄糖转运蛋白1(SGLT - 1)。CGGM患者由于肠道对葡萄糖的摄取受损而出现新生儿期渗透性腹泻。在此,我们报告一例41岁患有CGGM的女性,因低血糖症状转诊至我们诊所,最终诊断为胰岛素瘤,并成功切除。肿瘤DNA的全基因组测序显示染色体畸变,未发现驱动突变。鉴于成年期SGLT - 1功能丧失的长期后遗症尚不清楚,这例CGGM患者中的首例胰岛素瘤可能揭示了一种因数十年葡萄糖稳态失衡而产生的新表型。我们推测SGLT - 1可能在胰腺β细胞可塑性中发挥作用,并提出CGGM患者成年期患胰岛素瘤风险可能更高的机制。
这是CGGM患者中首例有记录的胰岛素瘤病例,提示葡萄糖吸收障碍与胰腺神经内分泌肿瘤之间可能存在新的联系。SLC5A1基因突变导致的SGLT - 1功能丧失突变可能影响胰腺β细胞可塑性,可能通过改变葡萄糖稳态导致胰岛素瘤发展。患者长期高脂肪、低碳水化合物饮食可能通过增加胰高血糖素样肽 - 1(GLP - 1)和葡萄糖依赖性促胰岛素多肽(GIP)水平刺激β细胞,这两种物质均促进β细胞增殖和存活。